Novel Approaches for Epigenetic Therapy for Relapsed Acute Lymphoblastic Leukemia |
The Johns Hopkins University School of Medicine / Linda Resar, MD & Andrei Thomas-Tikhonenko, PhD |
Innovation Grants |
2017 |
Maryland |
Establishing surrogate markers of angiogenesis in pediatric oncology phase I and II clinical trials: A Children’s Oncology Group study
|
Hospital for Sick Children / Sylvain Baruchel, MD |
Innovation Grants |
2007 |
Ontario |
Identification and validation of new therapeutic targets in pediatric leukemia through an aneuploidy-based synthetic lethality screen |
Dana-Farber Cancer Institute / David Pellman, MD |
Innovation Grants |
2012 |
Massachusetts |
Pediatric Osteosarcoma: Identifying the elusive molecular signature and its relationship to this disease |
St. Jude Children’s Research Hospital / Linda Hendershot, PhD |
Innovation Grants |
2019 |
Tennessee |
Treating Brain Tumor by Changing Cell Division Pattern |
Yale School of Medicine / Weimin Zhong |
Innovation Grants |
2010 |
Connecticut |
Modeling the Multi-hit Pathogenesis of t(12;21) Associated Pediatric ALL by CRISPR/Cas-mediated Genome Engineering |
Massachusetts General Hospital / Hanno Hock, M.D., Ph.D. |
Innovation Grants |
2014 |
Massachusetts |
Developing Novel Transcription Factor PROTACs to Disrupt the HMGA1 Epigenome in Relapsed Leukemia |
The Johns Hopkins University School of Medicine / Linda Resar, MD and Jian Jin, PhD |
Innovation Grants |
2022 |
Maryland |
Role of Protocadherin-9 in Enabling Leukemia Cell Colonization of the CNS |
National Jewish Health / Jordan Jacobelli, PhD |
Innovation Grants |
2017 |
Colorado |
Adoptive immunotherapy using clinical-grade T cells.
|
University of Texas M.D. Anderson Cancer Center / Laurence Cooper, MD, PhD |
Innovation Grants |
2007 |
Texas |
Casein Kinase 1 alpha Agonists as Novel Medulloblastoma Inhibitors |
University of Miami Miller School of Medicine / David Robbins, PhD |
Innovation Grants |
2012 |
Florida |